Multiple myeloma: evolving genetic events and host interactions.
about
Biological activity of lenalidomide and its underlying therapeutic effects in multiple myelomaDeficient spindle assembly checkpoint in multiple myelomaCancer-selective targeting of the NF-κB survival pathway with GADD45β/MKK7 inhibitorsDEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survivalIllegitimate WNT signaling promotes proliferation of multiple myeloma cellsAdvances in understanding monoclonal gammopathy of undetermined significance as a precursor of multiple myelomaDownregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma developmentMonoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective studyFGF signaling inhibits the proliferation of human myeloma cells and reduces c-myc expressionInterpretation of cytogenetic results in multiple myeloma for clinical practiceThe Effect of Hypoxia on Mesenchymal Stem Cell BiologyIntegrated analysis of whole-genome paired-end and mate-pair sequencing data for identifying genomic structural variations in multiple myelomaMany multiple myelomas: making more of the molecular mayhemMolecular pathogenesis of multiple myeloma: basic and clinical updatesDevelopment of Novel Immunotherapies for Multiple MyelomaTowards Stratified Medicine in Plasma Cell MyelomaThe myeloma stem cell concept, revisited: from phenomenology to operational termsAmplification and overexpression of CKS1B at chromosome band 1q21 is associated with reduced levels of p27Kip1 and an aggressive clinical course in multiple myelomaDLC1 tumor suppressor gene inhibits migration and invasion of multiple myeloma cells through RhoA GTPase pathwayComputational modeling of interactions between multiple myeloma and the bone microenvironmentTranscriptional repression of Bim by a novel YY1-RelA complex is essential for the survival and growth of Multiple MyelomaProgressively impaired proteasomal capacity during terminal plasma cell differentiation.An unusual H-Ras mutant isolated from a human multiple myeloma line leads to transformation and factor-independent cell growth.Arylazopyrazole AAP1742 inhibits CDKs and induces apoptosis in multiple myeloma cells via Mcl-1 downregulation.A library of gene expression signatures to illuminate normal and pathological lymphoid biology.Endothelial cell-driven regulation of CD9 or motility-related protein-1 expression in multiple myeloma cells within the murine 5T33MM model and myeloma patients.Serum YKL-40 concentrations in newly diagnosed multiple myeloma patients and YKL-40 expression in malignant plasma cells.Immunophenotypic studies of monoclonal gammopathy of undetermined significanceBortezomib plus thalidomide for newly diagnosed multiple myeloma in China.A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple MyelomaIn multiple myeloma, 14q32 translocations are nonrandom chromosomal fusions driving high expression levels of the respective partner genes.Effects of triptolide on RIZ1 expression, proliferation, and apoptosis in multiple myeloma U266 cellsPleiotropic anti-myeloma activity of ITF2357: inhibition of interleukin-6 receptor signaling and repression of miR-19a and miR-19bLymphoma stem cells: enough evidence to support their existence?Alterations in the antigen processing-presenting machinery of transformed plasma cells are associated with reduced recognition by CD8+ T cells and characterize the progression of MGUS to multiple myelomaTPL2 kinase regulates the inflammatory milieu of the myeloma nicheThe sumoylation pathway is dysregulated in multiple myeloma and is associated with adverse patient outcome.Chromatin architecture near a potential 3' end of the igh locus involves modular regulation of histone modifications during B-Cell development and in vivo occupancy at CTCF sites.Applying mass spectrometry based proteomic technology to advance the understanding of multiple myeloma.The t(14;20) is a poor prognostic factor in myeloma but is associated with long-term stable disease in monoclonal gammopathies of undetermined significance
P2860
Q21285161-3C250DFA-DE0D-4C43-BA27-B48A8A336374Q21560908-4B71F4D9-0FFF-4340-A1A2-453FFA641E60Q24305602-ECC9ACEC-92F4-4B0F-B30D-9CF805D50E49Q24311448-80AB413B-4E32-4C49-AEEB-30DD9EE96BB0Q24568035-6CD8BAE7-0313-4940-8056-024C2EE1F156Q24619589-C6268740-1C30-4C06-A89A-08484DC415BCQ24628811-B830A7CC-506B-4740-B643-74A295AF3472Q24653006-3A87664B-BB9A-4C3C-98F0-65C8FF2D8896Q24804513-09DD3089-0807-43F9-BA36-D848885EDBA1Q26777803-5052EF23-E0B3-40EC-81A6-BDBFC679778EQ26799883-5BA3F908-64DF-4E57-AF83-1219CB3DC27FQ26829846-F2972821-B095-46EA-96B0-5B1EDBB6288AQ26852892-3C44E8A9-FA8E-4E9D-99AC-DD8B4208DE0BQ27026205-56923BD8-7599-4C27-B80D-6B963377DA62Q28066890-7EDE38DB-B9ED-42D8-9ABF-5E94671DDF68Q28074994-DB5575D2-90BA-40EB-9390-1B6011714A7CQ28076070-C48DCA88-8D13-493E-8B56-A847E397AA04Q28274310-D6BE2738-F5B2-4A38-99EE-38E8ED3C928EQ28392462-CBED9DE1-66D4-4696-9291-CB6D0F402818Q28477867-7E340A05-DF61-421A-A49C-93B5A6C7FF62Q28534603-17C66049-D5E2-48F7-B86E-A704CBB5BCFCQ30476988-47FC3299-1AB5-4B6F-ADC3-E5D246D33F38Q30885275-68993FD8-9FED-4D1B-8FDC-9EE1553327D2Q31160552-EDA497FC-37B3-4FE1-8FD8-1D2E3B830A60Q33240316-24D51B77-3A71-4A4B-A2AC-669789E1D0DEQ33253492-65517567-AE17-4297-9DE5-4A0FDFF99626Q33255102-64E17DA5-B11B-413C-9896-9B1A1C0A4E87Q33387979-6C35216C-A6FE-4F76-91F9-2EE071060E1EQ33391566-48886ACB-19E6-4D31-91B5-044D07B051B3Q33426534-EABC1BAD-D719-47FF-8C15-6C8205A0C008Q33590961-8A1CE65E-8CC7-4575-91E9-E0BE6621EE03Q33593796-3FDC881D-20D0-4F59-A47D-29BAD89BD37EQ33632244-E346E0ED-682B-486B-8028-CBFFF0A160B8Q33632266-9F172E96-9D20-4834-991F-339D2FC4EFC9Q33677445-EF271500-8F7F-4036-A380-29AC1CA73615Q33714724-9E5FAB1A-4E2F-4CCB-BCA2-6138612050BCQ33788682-51BB22BC-3104-4D48-BB67-542B547F1323Q33823918-5A9F2C16-5379-43E2-A39E-70FF7E14924CQ33846310-FB7ADB09-00C0-4075-AFEF-9B8F09F482BDQ33952861-D8E7E0E3-8042-4598-95B1-A1B038ED1F26
P2860
Multiple myeloma: evolving genetic events and host interactions.
description
2002 nî lūn-bûn
@nan
2002 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի մարտին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Multiple myeloma: evolving genetic events and host interactions.
@ast
Multiple myeloma: evolving genetic events and host interactions.
@en
Multiple myeloma: evolving genetic events and host interactions.
@nl
type
label
Multiple myeloma: evolving genetic events and host interactions.
@ast
Multiple myeloma: evolving genetic events and host interactions.
@en
Multiple myeloma: evolving genetic events and host interactions.
@nl
prefLabel
Multiple myeloma: evolving genetic events and host interactions.
@ast
Multiple myeloma: evolving genetic events and host interactions.
@en
Multiple myeloma: evolving genetic events and host interactions.
@nl
P356
P1476
Multiple myeloma: evolving genetic events and host interactions.
@en
P2093
P Leif Bergsagel
W Michael Kuehl
P2888
P304
P356
10.1038/NRC746
P407
P577
2002-03-01T00:00:00Z
P5875
P6179
1012096528